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Calculated molecular properties of the novel heterofused quinolines and related 
compounds.a 
Compd miLogP TPSA MW nON nOHNH nrotb volume nviolations 
1 6.64 28.16 442.01 3 1 6 411.95 1 
2 5.89 42.15 413.95 3 2 4 377.47 1 
3 5.89 42.15 413.95 3 2 4 377.47 1 
26 4.30 48.71 305.77 3 1 1 260.85 0 
27 4.82 48.71 319.80 3 1 1 277.65 0 
28 5.09 48.71 333.82 3 1 1 294.45 1 
29 4.82 48.71 319.80 3 1 1 277.65 0 
30 3.73 50.94 309.80 3 3 2 272.08 0 
31 4.25 50.94 323.83 3 3 2 288.88 0 
32 4.52 50.94 337.85 3 3 2 305.68 0 
33 4.25 50.94 323.83 3 3 2 288.88 0 
35 3.67 62.71 321.81 3 2 4 287.38 0 
37 4.31 45.05 324.81 3 1 1 286.44 0 
38 5.02 45.92 320.78 3 0 1 274.23 1 
39 4.45 48.15 324.81 3 2 2 285.46 0 
42 4.40 35.27 285.73 3 0 1 238.94 0 
43 5.04 22.13 301.80 2 0 1 248.08 1 
44 3.62 46.26 287.75 3 1 4 248.81 0 
45 4.26 33.12 303.81 2 1 4 257.96 0 
47 4.08 36.68 298.80 2 0 3 250.00 0 
49 5.33 16.13 356.92 2 0 5 319.09 1 
50 5.68 16.13 358.94 2 0 7 329.45 1 
a Molecular properties (Log P, topological polar surface area (TPSA), molecular weight 
(MW), number of hydrogen bond acceptors (nON), number of hydrogen bond donors 
(nOHNH), number of rotatable bonds (nrotb), molecular volume, and number of 







Calculated CNS MPO desirability scores of the novel heterofused quinolines and related 
compounds.a 
Compd pKab cLogPb cLogDb CNS MPO 
1 9.75 7.0 4.44 1.8 
2 9.39 6.21 3.98 2.4 
3 9.43 6.21 4.13 2.4 
26 6.84 4.14 4.03 4.3 
27 6.87 4.58 4.47 4.0 
28 6.87 5.03 4.91 3.8 
29 6.93 4.58 4.46 4.0 
30 9.43 3.41 1.31 4.2 
31 9.43 3.85 1.74 4.0 
32 9.43 4.30 2.19 3.7 
33 9.43 3.85 1.74 4.0 
35 10.05 4.48 1.99 3.8 
37 2.38 3.96 3.96 4.4 
38 4.63 4.95 4.95 4.0 
39 9.43 4.22 2.23 4.1 
42 2.80 4.16 4.16 4.2 
43 3.63 4.87 4.87 3.2 
44 1.32 3.79 3.79 4.5 
45 2.14 4.51 4.51 3.7 
47 1.64 4.69 4.69 4.0 
49 9.86 5.63 3.20 2.5 
50 10.06 5.93 3.33 2.3 
a CNS MPO scores calculated using the algorithm reported in ref. [1]. TPSA values, 
MW, and the number of hydrogen bond donors (nOHNH), used in the algorithm, are 
shown in Table S1. 







Reported and experimental permeability values (Pe 10–6 cm s–1) of the 14 commercial 
drugs used for the PAMPA-BBB assay validation. 
Compound  Literature valuea Experimental valueb  
Cimetidine 0.0 0.70 ± 0.03 
Lomefloxacin 1.1 0.70 ± 0.04 
Norfloxacin 0.1 0.90 ± 0.02 
Ofloxacin 0.8 0.98 ± 0.04 
Hydrocortisone 1.9 1.40 ± 0.05 
Piroxicam 2.5 1.80 ± 0.02 
Clonidine 5.3 6.50 ± 0.05 
Corticosterone 5.1 6.70 ± 0.10 
Imipramine 13 12.3 ± 0.10 
Promazine 8.8 13.8 ± 0.30 
Progesterone 9.3 16.8 ± 0.30 
Desipramine 12 17.8 ± 0.10 
Testosterone 17 23.1 ± 0.20 
Verapamil 16 25.8 ± 0.30 
a
 Taken from ref. [2]. 
b
 Values are expressed as the mean ± SD of three independent experiments. 
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1H NMR (400 MHz , CDCl3)
S28
4-{9-Chloro-3,4,4a,5,6,10b -hexahydro-2H-pyrano[3,2-c]quinolin-5-yl}benzonitrile 37





































































































13C NMR (100.6 MHz, CD3OD)
· 2HCl
S47
